Telix Pharmaceuticals has signed letters of intent to collaborate with EDAP TMS and Profound Medical to explore the use of its PSMA-PET imaging agents in advanced minimally invasive prostate cancer treatments. The partnerships aim to improve patient selection, treatment planning, and monitoring by integrating molecular imaging with robotic and MRI-guided therapies like high-intensity focused ultrasound and transurethral ultrasound ablation. These collaborations seek to enhance personalized care, reduce side effects, and accelerate adoption of novel therapeutic workflows in prostate cancer management. The focus will be on scientific and educational research to establish best practices for these emerging treatments.
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
